
Ready Capital Corporation 5.75%
RCC
Updated: 23/09/2026, 13:12:23
Ready Capital Corporation (RCC) functions as a real estate finance enterprise, primarily engaged in the acquisition, management, and funding of small balance commercial (SBC) loans. Its operations are structured into three distinct divisions: SBC Lending and Acquisitions, Small Business Lending, and Residential Mortgage Banking. The SBC Lending and Acquisitions division, managed by its subsidiary ReadyCap Commercial, LLC, handles SBC loans across the full spectrum of a property's lifecycle, including origination channels for construction, bridge, stabilized, and agency loans. Through its wholly-owned subsidiary, ReadyCap Lending, LLC, the Small Business Lending segment is responsible for sourcing, originating, and servicing owner-occupied loans guaranteed by the Small Business Administration (SBA) under its Section 7(a) Program. The Residential Mortgage Banking segment, operating via its subsidiary GMFS, LLC, specializes in originating residential mortgage loans. Established in November 2011, the company maintains its corporate headquarters in New York, NY.
No summaries found.
- Share price
- $25.04
- Market cap
- $4.06B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Thomas Edward Capasse
- Employees
- 475
- IPO date
- 16/02/2021
- Beta
- 0.36310706
- Last dividend
- $0.00
- Day range
- $25.04 – $25.06
- 52-week range
- $23.97 – $26.87
- 1-day performance
- 0.04%
- 1-year performance
- 4.46%
- Current drawdown (1Y)
- -6.81%
- CIK
- 0001527590
- CUSIP
- 75574U606
- ISIN
- US75574U6064
- Created
- 07/12/2025, 13:55:48
- Last update
- 23/09/2026, 13:12:23
Track Ready Capital Corporation 5.75% with an AI analyst
See which prediction-market events move RCC, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Business Wire • STOCK • 21/04/2026, 08:45:00
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
Business Wire • STOCK • 28/02/2026, 11:05:00
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Business Wire • STOCK • 28/02/2026, 11:00:00